Exogenous bovine thrombin as a biomarker of exposure and outcome

References

• Boldt J, Huttner I, Suttner S et al. Changes of haemostasis in patients undergoing major abdominal surgery – is there a difference between elderly and younger patients? Br. J. Anaesth.87(3), 435–440 (2001).
   PubMed Web of Science ®Google Scholar
• Fareed J, Bick RL, Hoppensteadt DA, Bermes EW Jr. Molecular markers of hemostatic activation: applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin. Appl. Thromb. Hemost.1(2), 87–102 (1995).
   Google Scholar
• Whitton C, Sands D, Lee T, Chang A, Longstaff C. A reunification of the US (“NIH”) and International Unit into a single standard for Thrombin. Thromb. Haemost.93(2), 261–266 (2005).
   Google Scholar
• Fareed J, Bick RL, Squillaci G, Walenga JM, Bermes EW Jr. Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin. Chem.29(9), 1641–1658 (1983).
   Google Scholar
• Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol.23(1), 17–25 (2003).
   PubMed Web of Science ®Google Scholar
• Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can. J. Anaesth.53(6 Suppl.), S2–S11 (2006).
   Web of Science ®Google Scholar
• Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol.153(Suppl. 1), S263–S282 (2008).
   Web of Science ®Google Scholar
• Alving BM, Weinstein MJ, Finlayson JS, Menitove JE, Fratantoni JC. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion35(9), 783–790 (1995).
   PubMed Web of Science ®Google Scholar
• Dorion RP, Hamati HF, Landis B et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch. Pathol. Lab. Med.122(10), 887–894 (1998).
   PubMed Web of Science ®Google Scholar
• von Oppell UO, Zilla P. Tissue adhesives in cardiovascular surgery.J. Long Term Eff. Med. Implants8(2), 87–101 (1998).
   PubMed Web of Science ®Google Scholar
• Mintz PD, Mayers L, Avery N et al. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center. Ann. Clin. Lab. Sci.31(1), 108–118 (2001).
   PubMed Web of Science ®Google Scholar
• Lundblad RL, Bradshaw RA, Gabriel D et al. A review of the therapeutic uses of thrombin. Thromb. Haemost.91(5), 851–860 (2004).
   PubMed Web of Science ®Google Scholar
• Flaherty MJ, Wener MH. Antibodies to thrombin in postsurgical patients. Blood73(5), 1386 (1989).
   Google Scholar
• Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion42(1), 18–26 (2002).
   PubMed Web of Science ®Google Scholar
• Lee DI, Uribe C, Eichel L et al. Sealing percutaneous nephrolithotomy tracts with gelatin matrix hemostatic sealant: initial clinical use. J. Urol.171(2 Pt 1), 575–578 (2004).
   PubMed Web of Science ®Google Scholar
• Milkes DE, Friedland S, Lin OS, Reid TR, Soetikno RM. A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostat. Gastrointest. Endosc.55(6), 735–740 (2002).
   Google Scholar
• Muntean W, Zenz W, Finding K, Zobel G, Beitzke A. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr.83(1), 84–87 (1994).
   PubMed Web of Science ®Google Scholar
• Crow SS, Sullivan VV, Aysola AE et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann. Thorac. Surg.83(4), 1547–1549 (2007).
   Web of Science ®Google Scholar
• Lawson JH, Lynn KA, Vanmatre RM et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann. Thorac. Surg.79(3), 1037–1038 (2005).
   PubMed Web of Science ®Google Scholar
• Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann. Intern. Med.111(8), 631–634 (1989).
   PubMed Web of Science ®Google Scholar
• Neschis DG, Heyman MR, Cheanvechai V, Benjamin ME, Flinn WR. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. J. Vasc. Surg.35(2), 400–402 (2002).
   Google Scholar
• Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am. J. Med.118(7), 805 (2005).
   Web of Science ®Google Scholar
• Winterbottom N, Kuo J, Nguyen K et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J. Applied Res.2(1), 1–11 (2002).
   Google Scholar
• The CoStasis Multi-center Collaborative Writing Committee. A novel collagen-based composite offers effective hemostasis for multiple surgical indications: results of a randomized controlled trial. Surgery129(4), 445–450 (2001).
   PubMed Web of Science ®Google Scholar
• Kajitani M, Ozdemir A, Aguinaga M et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J. Card. Surg.15(6), 378–382 (2000).
   PubMed Web of Science ®Google Scholar
• Nelson PA, Powers JN, Estridge TD et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J. Biomed. Mater. Res.58(6), 710–719 (2001).
   PubMed Web of Science ®Google Scholar
• Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am. J. Clin. Pathol.97(1), 84–91 (1992).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Craven S et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb. Haemost.94(5), 958–964 (2005).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb. Haemost.99(5), 819–829 (2008).
   PubMed Web of Science ®Google Scholar
• Brennan M. Fibrin glue. Blood Rev.5(4), 240–244 (1991).
   PubMed Web of Science ®Google Scholar
• Marques AC, Yu PC, Calderaro D, Gualandro DM, Caramelli B. High-risk patients undergoing major vascular surgery: to operate or not to operate? J. Am. Coll. Cardiol.50(14), 1398–1399; author reply 1399 (2007).
   Google Scholar
• Yau TM, Borger MA, Weisel RD, Ivanov J. The changing pattern of reoperative coronary surgery: trends in 1230 consecutive reoperations. J. Thorac. Cardiovasc. Surg.120(1), 156–163 (2000).
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Jones EL, Craver JM, Grosswald R, Guyton RA. In-hospital and long-term outcome after reoperative coronary artery bypass graft surgery. Circulation92(9 Suppl.), II50–II57 (1995).
   Google Scholar
• Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb. Haemost.99(5), 851–862 (2008).
   PubMed Web of Science ®Google Scholar
• Desai SS, Massad MG, DiDomenico RJ et al. Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past? Recent Patents Cardiovasc. Drug Discov.1(3), 307–316 (2006).
   Google Scholar
• Martorell L, Martinez-Gonzalez J, Rodriguez C et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb. Haemost.99(2), 305–315 (2008).
   PubMed Web of Science ®Google Scholar
• Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann. Vasc. Surg.18(3), 349–351 (2004).
   PubMed Web of Science ®Google Scholar
• Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J. Reprod. Med.46(10), 909–912 (2001).
   PubMed Web of Science ®Google Scholar
• Zehnder JL, Leung LL. Immunological consequences of topical bovine thrombin. Am. J. Pathol.159(6), 2371 (2001).
   Google Scholar
• Christie RJ, Carrington L, Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery121(6), 708–710 (1997).
   PubMed Web of Science ®Google Scholar
• Muntean W, Zenz W, Edlinger G, Beitzke A. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb. Haemost.77(6), 1223 (1997).
   Web of Science ®Google Scholar
• Chouhan VD, De La Cadena RA, Nagaswami C et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb. Haemost.77(2), 343–349 (1997).
   PubMed Web of Science ®Google Scholar
• Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J. Neurosurg.78(5), 817–820 (1993).
   PubMed Web of Science ®Google Scholar
• Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am. J. Pediatr. Hematol. Oncol.16(3), 249–254 (1994).
   PubMedGoogle Scholar
• Cmolik BL, Spero JA, Magovern GJ, Clark RE. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J. Thorac. Cardiovasc. Surg.105(2), 222–227; discussion 227–228 (1993).
   PubMed Web of Science ®Google Scholar
• Banninger H, Hardegger T, Tobler A et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br. J. Haematol.85(3), 528–532 (1993).
   PubMed Web of Science ®Google Scholar
• Stricker RB, Lane PK, Leffert JD et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood72(4), 1375–1380 (1988).
   Google Scholar
• Carroll JF, Moskowitz KA, Edwards NM et al. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb. Haemost.76(6), 925–931 (1996).
   PubMed Web of Science ®Google Scholar
• Mohler ER III, Mitchell ME, Carpenter JP et al. Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience. Vasc. Med.6(4), 241–244 (2001).
   PubMedGoogle Scholar
• Richter F, Schnorr D, Deger S et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology61(1), 73–77 (2003).
   PubMed Web of Science ®Google Scholar
• Vannorsdall MD, Arkel YS, Ku DH, Lucas FL, Himmelfarb J. Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis. Kidney Int.64(2), 690–696 (2003).
   Google Scholar
• Gill IS, Ramani AP, Spaliviero M et al. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology65(3), 463–466 (2005).
   Google Scholar
• Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose a1–3galactose. J. Clin. Immunol.20(6), 434–444 (2000).
   PubMed Web of Science ®Google Scholar
• Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann. Surg.233(1), 88–96 (2001).
   PubMed Web of Science ®Google Scholar
• Fastenau DR, McIntyre JA. Immunochemical analysis of polyspecific antibodies in patients exposed to bovine fibrin sealant. Ann. Thorac. Surg.69(6), 1867–1872 (2000).
   Google Scholar
• McNeil NL, Clark TW. Sonographically guided percutaneous thrombin injection versus sonographically guided compression for femoral artery pseudoaneurysms. AJR Am. J. Roentgenol.176(2), 459–462 (2001).
   Google Scholar
• Barret JP, Dziewulski P, Wolf SE et al. Effect of topical and subcutaneous epinephrine in combination with topical thrombin in blood loss during immediate near-total burn wound excision in pediatric burned patients. Burns25(6), 509–513 (1999).
   PubMed Web of Science ®Google Scholar
• Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. Otolaryngol. Head Neck Surg.131(5), 601–605 (2004).
   PubMed Web of Science ®Google Scholar
• Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope115(5), 899–902 (2005).
   PubMed Web of Science ®Google Scholar
• Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol.27(8), 1687–1693 (2007).
   PubMed Web of Science ®Google Scholar